This 8 week at home study is designed to explore efficacy endpoints and evaluate the safety of intranasal Bremelanotide in women with Female Sexual Arousal Disorder. Efficacy will be assessed vs. a parallel placebo group.

Inclusion Criteria:

• Post menopausal and in general good health
• In a stable relationship with a male partner for at least 6 months
• Willing to attempt sexual activity once a week with your partner